Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
RDHL RedHill Biopharma Ltd. daily Stock Chart
RDHL [NASD]
RedHill Biopharma Ltd.
Healthcare | Biotechnology | Israel
financial highlights | statements
Index- P/E- EPS (ttm)-2.58 Insider Own6.98% Shs Outstand171.68M Perf Week1.29%
Market Cap1.22B Forward P/E- EPS next Y-0.32 Insider Trans0.00% Shs Float18.25M Perf Month42.08%
Income- PEG- EPS next Q-0.46 Inst Own18.16% Short Float1.80% Perf Quarter12.72%
Sales4.01M P/S303.77 EPS this Y33.50% Inst Trans- Short Ratio3.96 Perf Half Y39.29%
Book/sh2.12 P/B3.34 EPS next Y81.50% ROA- Target Price22.00 Perf Year-29.03%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range4.30 - 11.25 Perf YTD37.94%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-36.98% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low64.88% ATR0.32
Employees74 Current Ratio- Sales Q/Q1901.00% Oper. Margin- RSI (14)73.35 Volatility3.03% 5.28%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.10 Prev Close7.11
ShortableYes LT Debt/Eq- EarningsMay 09 Payout- Avg Volume83.16K Price7.09
Recom2.00 SMA2016.45% SMA5028.10% SMA2007.67% Volume7,936 Change-0.28%
Jan-26-18Initiated Nomura Buy $18
Oct-06-17Initiated Seaport Global Securities Buy $19
Oct-04-17Reiterated H.C. Wainwright Buy $33 → $36
Feb-24-17Reiterated FBR & Co. Outperform $36 → $25
Jul-27-16Reiterated FBR Capital Outperform $33 → $36
Sep-29-15Initiated Nomura Buy
Jul-29-15Reiterated ROTH Capital Buy $30 → $31
Jun-17-15Reiterated H.C. Wainwright Buy $23 → $32
Jun-15-15Reiterated ROTH Capital Buy $27.50 → $30
May-14-18 08:00AM  RedHill Biopharma to Host Investor Webcast on RHB-104 for Crohns Disease on May 15 GlobeNewswire +9.73%
May-08-18 07:00AM  RedHill Biopharma Reports First Quarter 2018 Financial Results GlobeNewswire +7.02%
May-07-18 11:48AM  Durham pharma eyes potential approval of drug in roughly $5B market American City Business Journals
08:00AM  RedHill Biopharma Announces Last Patient Assessed for Primary Endpoint in RHB-104 Phase III Study for Crohns Disease GlobeNewswire
May-04-18 07:00AM  RedHill Biopharma Announces Enrollment of 300th Patient in Confirmatory Phase III Study with TALICIA® for H. pylori Infection GlobeNewswire
May-01-18 07:00AM  RedHill Biopharma to Host First Quarter 2018 Financial Results Conference Call on May 8, 2018 GlobeNewswire
Apr-10-18 08:20AM  Report: Exploring Fundamental Drivers Behind Itau Unibanco Holding S.A, Weibo, Redhill Biopharma, Shenandoah Telecommunications, Grifols, S.A, and Orthofix International N.V New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Apr-09-18 02:10PM  RedHill revenues up 31 percent in Q4 American City Business Journals
07:00AM  RedHill Biopharma Provides Semi-Annual Business Update GlobeNewswire
12:49AM  BRIEF-Swire Pacific Announces Sale Of Residential Unit For HK$120 Million By Redhill Properties Reuters
Mar-27-18 12:35PM  Sainsbury's needs year's notice to act on post-Brexit trade deal Reuters -9.21%
08:00AM  RedHill Biopharma Announces Two Oral Presentations on BEKINDA® 24 mg for acute gastroenteritis at the SAEM 2018 Annual Meeting GlobeNewswire
Mar-26-18 08:00AM  RedHill Biopharma Announces DDW 2018 Poster of Distinction on Positive Phase II Results with BEKINDA® for IBS-D GlobeNewswire
Mar-20-18 08:00AM  RedHill Biopharma to Present at H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswire
Mar-19-18 07:00AM  RedHill Biopharma Announces Poster Presentation on New Potential Therapeutic Applications of RHB-107 at the AACR 2018 Annual Meeting GlobeNewswire
Mar-15-18 07:45AM  Market Trends Toward New Normal in Golden Ocean Group, Redhill Biopharma, Galapagos NV, Crawford, Amphastar Pharmaceuticals, and 51job Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Feb-22-18 07:00AM  RedHill Biopharma Provides Fourth Quarter and Full-Year 2017 Investor Update GlobeNewswire
Feb-13-18 07:00AM  RedHill Biopharma to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call on February 22, 2018 GlobeNewswire
Feb-01-18 07:00AM  RedHill Biopharma to Present at BIO CEO & Investor Conference GlobeNewswire
Jan-30-18 09:01AM  RedHill Biopharma (RDHL) in Focus: Stock Moves 10.2% Higher Zacks
Jan-17-18 07:00AM  RedHill Biopharma and Express Scripts Subsidiary Inside Rx Add EnteraGam® to Savings Program for Uninsured or Underinsured Patients GlobeNewswire
Jan-16-18 08:00AM  RedHill Biopharma Announces Final Results from Phase II Study with BEKINDA® for IBS-D GlobeNewswire
Dec-28-17 02:10PM  RedHill teams with Mayo Clinic, MD Anderson on new cancer trial American City Business Journals
Dec-22-17 07:00AM  RedHill Biopharma Announces Initiation of Phase IIa Study with ABC294640 (YELIVA®) for Cholangiocarcinoma at Mayo Clinic and MD Anderson GlobeNewswire
Dec-05-17 09:30AM  RedHill Biopharma Provides 2017 Year-End Business Update GlobeNewswire
Nov-15-17 08:45AM  RedHill grows revenue in third quarter, closes public offering American City Business Journals
Nov-13-17 01:33PM  RedHill Biopharma Announces Closing of Public Offering of its American Depositary Shares GlobeNewswire
07:50AM  RedHill Biopharma Reports 2017 Third Quarter Financial Results GlobeNewswire
07:30AM  RedHill Biopharma Reports 2017 Third Quarter Financial Results GlobeNewswire
Nov-09-17 07:01AM  RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn's Disease GlobeNewswire
Nov-08-17 09:21AM  RedHill Biopharma Prices Public Offering of its American Depositary Shares GlobeNewswire -29.60%
09:13AM  RedHill Biopharma Prices Public Offering of its American Depositary Shares GlobeNewswire
Nov-07-17 04:17PM  RedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares GlobeNewswire -9.63%
Nov-06-17 08:00AM  RedHill Biopharma to Host Third Quarter 2017 Financial Results Conference Call on November 13, 2017 GlobeNewswire -5.59%
07:00AM  RedHill Biopharma Announces EnteraGam® Poster Presentation at the ISPOR 20th Annual European Congress GlobeNewswire
Nov-01-17 07:01AM  RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT® for Migraines GlobeNewswire
Oct-26-17 08:48AM  Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics Zacks
07:00AM  RedHill Biopharma to Present at the BIO-Europe 2017 Conference GlobeNewswire
Oct-23-17 08:30AM  RedHill lands new orphan drug designation, looks to grow commercial portfolio American City Business Journals
07:20AM  Corporate News Blog - RedHill Receives FDA Orphan Drug Designation for MESUPRON for Treatment of Pancreatic Cancer ACCESSWIRE
07:00AM  RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering RHB-104 GlobeNewswire
Oct-20-17 07:00AM  RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer GlobeNewswire +5.35%
Oct-19-17 08:00AM  RedHill Biopharma Announces Poster Presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference GlobeNewswire
Oct-10-17 06:10AM  RedHill Biopharma to Present at the BioNetwork 2017 Partnering Summit GlobeNewswire
Oct-03-17 07:41AM  RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) GlobeNewswire -13.14%
07:00AM  RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) GlobeNewswire
Oct-02-17 08:30PM  RedHill Biopharma Ltd (RDHL): How Does It Impact Your Portfolio? Simply Wall St.
07:00AM  RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohns Disease with Top-Line Results Expected Mid-2018 GlobeNewswire
Sep-28-17 07:00AM  RedHill Biopharma to Announce Top-Line Results from BEKINDA® 12 mg Phase II Study for IBS-D on October 3rd, 2017 GlobeNewswire +10.56%
Sep-18-17 08:00AM  RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering its Combination Therapy for Hard-to-Treat Cancers GlobeNewswire
07:00AM  RedHill Biopharma to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-15-17 12:01PM  Is RedHill Biopharma Ltd (RDHL) Undervalued? Simply Wall St.
Sep-13-17 07:01AM  RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S. GlobeNewswire
Sep-07-17 08:00AM  RedHill Biopharma to Present at the 10th Annual BioPharm America International Partnering Conference GlobeNewswire
Aug-31-17 07:00AM  RedHill Biopharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire
Aug-17-17 02:55PM  RedHill keen on growth makes another commercial play American City Business Journals
07:01AM  RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules GlobeNewswire
Aug-10-17 08:01AM  RedHill Biopharma Provides 2017 Semi-Annual Business Update GlobeNewswire
Jul-31-17 08:02AM  RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn's Disease GlobeNewswire
Jul-27-17 11:51AM  RedHill Biopharma Ltd. :RDHL-US: Earnings Analysis: Q2, 2017 By the Numbers : July 27, 2017 Capital Cube -5.17%
07:00AM  Corporate News Blog - FDA Grants Fast Track Designation to Flex Pharmas FLX-787 for the Treatment of Severe Muscle Cramps Associated with ALS ACCESSWIRE
Jul-25-17 01:40PM  RedHill Biopharma reports initial revenues in Q2 as it grows Raleigh ops American City Business Journals +7.58%
07:22AM  RedHill Biopharma Reports 2017 Second Quarter Financial Results GlobeNewswire
07:00AM  RedHill Biopharma Reports 2017 Second Quarter Financial Results GlobeNewswire
Jul-18-17 07:00AM  RedHill Biopharma to Host Second Quarter 2017 Financial Results Conference Call on July 25, 2017 GlobeNewswire
Jul-17-17 08:01AM  RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D GlobeNewswire
Jul-12-17 08:01AM  RedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn's Disease GlobeNewswire
Jun-19-17 06:00AM  RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA® for Acute Gastroenteritis GlobeNewswire +5.58%
Jun-15-17 08:01AM  RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA(TM)) for H. pylori Infection GlobeNewswire
08:00AM  RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA) for H. pylori Infection GlobeNewswire
Jun-14-17 08:01AM  RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA® for Acute Gastroenteritis GlobeNewswire
Jun-13-17 08:02AM  RedHill Biopharma Initiates Promotion of Donnatal® and EnteraGam® in the U.S. GlobeNewswire
08:00AM  RedHill Biopharma Initiates Promotion of Donnatal® and EnteraGam® in the U.S. GlobeNewswire
08:00AM  Concordia International Corp. Announces RedHill Biopharma Has Started Promoting Donnatal® in the U.S. CNW Group
Jun-06-17 07:00AM  RedHill Biopharma to Present at the 2017 BIO International Convention GlobeNewswire
May-04-17 08:00AM  RedHill Biopharma Announces Poster Presentation of the Positive RHB-105 Phase III Results for H. pylori Infection at Digestive Disease Week 2017 GlobeNewswire
May-03-17 06:02AM  RedHill Biopharma Reports 2017 First Quarter Financial Results GlobeNewswire
Apr-25-17 07:00AM  RedHill Biopharma to Host First Quarter 2017 Financial Results Conference Call on May 3, 2017 GlobeNewswire
Apr-24-17 07:01AM  RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA® Phase II Study for IBS-D GlobeNewswire
Apr-20-17 07:00AM  RedHill Biopharma Announces Peer-Reviewed Publication of the Positive YELIVA® Phase I Study Results in Advanced Solid Tumors GlobeNewswire
Apr-19-17 07:00AM  RedHill Biopharma to Host R&D Day on BEKINDA® for Acute Gastroenteritis and IBS-D GlobeNewswire
Apr-18-17 08:01AM  RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA® GlobeNewswire
Apr-13-17 06:00AM  RedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT® for Migraines in Luxembourg GlobeNewswire
Apr-05-17 11:22AM  Company News for April 05, 2017 Zacks
11:22AM  Company News for April 05, 2017
07:01AM  RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam® GlobeNewswire
07:01AM  RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam®
Apr-04-17 06:06AM  RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA® for the Treatment of Cholangiocarcinoma GlobeNewswire
06:06AM  RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA® for the Treatment of Cholangiocarcinoma
Mar-30-17 07:00AM  RedHill Biopharma to Present at BioCentury Future Leaders in the Biotech Industry Conference GlobeNewswire
Mar-22-17 07:00AM  RedHill Biopharma to Present at the 2017 MAP Conference GlobeNewswire
Mar-21-17 09:02AM  RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn's Disease GlobeNewswire
09:00AM  RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohns Disease GlobeNewswire
Mar-14-17 02:49PM  RedHill Biopharma Ltd. :RDHL-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Capital Cube
02:49PM  RedHill Biopharma Ltd. :RDHL-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Mar-13-17 08:00AM  RedHill Biopharma to Present at the BIO-Europe Spring 2017 Conference GlobeNewswire
Mar-07-17 08:00AM  RedHill Biopharmas Co-Promotion Partner Concordia Announces U.S. District Court Grants Treble Damages Relating to Donnatal® GlobeNewswire
Mar-01-17 01:04PM  REDHILL BIOPHARMA LTD. Financials
Feb-23-17 10:07AM  RedHill Biopharma Announces Availability of Its Annual Report on Form 20-F Through Its Website GlobeNewswire
07:15AM  RedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results GlobeNewswire
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, and in-licensed/acquired drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company commercializes three gastrointestinal products in the United States, such as Donnatal, a prescription oral adjunctive drug used in the treatment of irritable bowel syndrome (IBS), and acute enterocolitis and duodenal ulcers; EnteraGam, a prescription medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools; and Esomeprazole Strontium Delayed-Release Capsules 49.3 mg, a prescription proton pump inhibitor drug product indicated for adults for the treatment of GERD, risk reduction of NSAID-associated gastric ulcer, Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence, and for pathological hypersecretory conditions. Its clinical-stage development programs include TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection with an ongoing confirmatory Phase III study and successful results from a first Phase III study; RHB-104 with an ongoing first Phase III study for Crohn's disease and a planned pivotal Phase III study for nontuberculous mycobacteria infections; BEKINDA (RHB-102) with positive results from a Phase III study in acute gastroenteritis and gastritis, and positive results from a Phase II study in IBS-D; YELIVA (ABC294640), a SK2 selective inhibitor, targeting multiple oncology, inflammatory, and gastrointestinal indications with an ongoing Phase IIa study for cholangiocarcinoma; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; and RHB-107 (MESUPRON), a Phase II-stage serine protease inhibitor targeting gastrointestinal and other solid tumor cancers. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
open in yahoo | open in reuters | open in google